However, this large population of MLPs was preserved when either motixafortide or plerixafor was added to G-CSF mobilization in patients with MM (26.18%), suggesting that MLPs may be uniquely reduced in the G-CSF mobilized HSPC graft of patients with MM and that the addition of CXCR4i with either motixafortide or plerixafor to G-CSF may preserve this population within the HSPC graft in those patients. This evidence concerns the gene CSF3 and Miyoshi myopathy.